AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Soligenix completes FLASH2 study with 50 patients, exceeds trial estimate.
ByAinvest
Wednesday, Nov 19, 2025 7:35 am ET1min read
Soligenix has completed enrollment of 50 patients in its Phase 3 study (FLASH2) evaluating HyBryte (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL). The interim analysis of the blinded response rate exceeds the trial estimate. HyBryte has shown promising results in previous studies, including a statistically significant Phase 3 study and a comparative study. The company is focused on developing and commercializing products for rare diseases where there is an unmet medical need.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet